or Try an Advanced Search...

    Technical Analysis for NRSN - NeuroSense Therapeutics Ltd.

    Grade Last Price % Change Price Change
    D 0.96 -3.53% -0.03
    NRSN closed down 11.2 percent on Wednesday, November 20, 2024, on 1.16 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NRSN trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish -3.52%
    Stochastic Reached Oversold Weakness -3.52%
    Below Lower BB Weakness -3.52%
    Down 3 Days in a Row Weakness -3.52%
    Down 4 Days in a Row Weakness -3.52%
    Down 5 Days in a Row Weakness -3.52%
    Lower Bollinger Band Touch Weakness -3.52%
    Oversold Stochastic Weakness -3.52%
    BB Squeeze Ended Range Expansion -14.33%
    Below Lower BB Weakness -14.33%
    Older End-of-Day Signals for NRSN ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 2 hours ago
    Down 3% about 2 hours ago
    Fell Below Previous Day's Low about 2 hours ago
    Down 2 % about 2 hours ago
    Up 3% about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    NRSN Chart by TradingView
    Basic chart:

    Profile

    NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Disease Neuroscience Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Neurodegeneration Senescence Gladstone Institutes

    Is NRSN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 21 NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
    Oct 28 NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
    Oct 28 EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
    Oct 24 New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
    Oct 15 NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
    Oct 9 NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
    Oct 7 NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
    Sep 24 NeuroSense regains compliance with minimum bid price rule
    Sep 24 NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
    Sep 24 NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
    See more NRSN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.33
    52 Week Low 0.512
    Average Volume 168,801
    200-Day Moving Average 1.22
    50-Day Moving Average 1.23
    20-Day Moving Average 1.26
    10-Day Moving Average 1.24
    Average True Range 0.10
    RSI (14) 30.07
    ADX 15.7
    +DI 16.94
    -DI 32.33
    Chandelier Exit (Long, 3 ATRs) 1.09
    Chandelier Exit (Short, 3 ATRs) 1.28
    Upper Bollinger Bands 1.42
    Lower Bollinger Band 1.09
    Percent B (%b) -0.3
    BandWidth 26.44
    MACD Line -0.01
    MACD Signal Line 0.02
    MACD Histogram -0.032
    Fundamentals Value
    Market Cap 13.53 Million
    Num Shares 13.7 Million
    EPS -0.94
    Price-to-Earnings (P/E) Ratio -1.05
    Price-to-Sales 0.00
    Price-to-Book 4.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.21
    Resistance 3 (R3) 1.22 1.17 1.17
    Resistance 2 (R2) 1.17 1.11 1.16 1.16
    Resistance 1 (R1) 1.08 1.08 1.05 1.06 1.15
    Pivot Point 1.03 1.03 1.01 1.02 1.03
    Support 1 (S1) 0.94 0.97 0.91 0.92 0.83
    Support 2 (S2) 0.88 0.94 0.87 0.82
    Support 3 (S3) 0.79 0.88 0.81
    Support 4 (S4) 0.77